China SXT Pharmaceuticals Inc. (SXTC) stock prices were up by 16.80% as of the market closing on October 26th, 2021. This brought the price per share up to USD$1.19. Subsequent premarket fluctuations saw the stock decline by 2.52%, bringing it up to USD$1.16.
SXTC Stock Receives PMP
October 18th2021 saw SXTC stock announced having received a new Pharmaceutical Manufacturing Permit (PMP) with a new production scope of lyophilization process. The PMP was granted by the Jiangso Province Medical Products Administration. The company also successfully passed its pharmaceutical GMP compliance-inspection, which was conducted by JSMPA for its new lyophilization production facility. Based on these developments, the company is confident in its pioneering of Directly Oral TCMP manufacturing nationwide across China.
Lyophilization processing is also referred to as freeze drying, a process wherein raw materials or products are frozen by the removal of frozen water by sublimation. Conducted in a vacuum, the ice is turned directly into vapor, bypassing the liquid phase. After the lyophilization process, the raw materials or products become loose and fragile, which facilitates their aqueous solubility. This process serves to result in the extension of the shelf life of the raw materials and products. Critically, this process helps the manufacturing of products such as the company’s Directly Oral TCMPs and After Soaking Oral TCMPs. These products have temperature sensitive components that remain unchanged as they are kept in a frozen and dry condition.
SXTC Stock’s Luxuejing
The manufacturing of the company’s Directly Oral TCMP product, Luxuejing, involved the lyophilization process. This helps the company in delivering better quality products. Luxuejing is a Chinese medicine that is made from fresh bloods of Cuerus Nippon, having been approved for use for approved indications. These indications include, but are not limited to, leukopenia, thrombocytopenia or hypoimmunity, chronic anemia, aplastic anemia, erectile dysfunction, and postoperative rehabilitation.
Scope of PMP
The permit for new production scope of lyophilization processing will serve to substantially contribute to its continued efforts in leading research and development. This R&D strategy is for new advanced TCMPs and pursuit of higher quality of the products. The SXTC stock is hopeful that this will further accelerate its efforts in regard to the R&D of new Advanced TCMPs.
Future Outlook for SXTC Stock
SCTX stock is poised to capitalize on the expanded scope of opportunities afforded to it as a result of its new PMP. The company is keen to maintain its trajectory of success in a bid to usher in unprecedented growth. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to facilitate consistent and organic increases in shareholder value over the long term.